Dermatology · New York, NY
NPI
1013902444
Since 2005
Specialty
Dermatology
Code 207N00000X
Group practices
0
Medicare group memberships
Hospitals
3
Hospital affiliations
5 E 98th St, 5th Floor Box 1048
New York, NY, 10029
Phone (212) 241-5778
Medicare paid, 2022
$41K
2,568 services
Medicare patients, 2022
258
Average age 78
Drug cost, 2024
$805K
838 prescriptions
Company payments, 2025
$154K
From 26 companies
Procedures and visits billed to Original Medicare, 2022
In 2022, the most common Medicare service billed by Mark Lebwohl was code 99214 (office e&m - established), 202 times for 179 patients. In total Mark Lebwohl billed 2,568 services in 34 codes, and Medicare paid $41K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-04-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 202 | 179 | $84.40 | $17K |
| 17003 Destruction Skin Lesion | Office | 74 | 30 | $6.45 | $477 |
| 11102 Skin Biopsy | Office | 58 | 53 | $89.00 | $5,162 |
| 99213 Office E&M - Established | Office | 56 | 56 | $55.91 | $3,131 |
| 17000 Destruction Skin Lesion | Office | 43 | 41 | $44.09 | $1,896 |
| 11103 Skin Biopsy | Office | 26 | 19 | $44.32 | $1,152 |
| 99204 Office E&M - New | Office | 15 | 15 | $105.65 | $1,585 |
| 99212 Office E&M - Established | Office | 14 | 13 | $33.21 | $465 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark Lebwohl prescribed most often to Medicare patients was Mometasone Furoate, with 93 prescriptions and refills. In total Mark Lebwohl wrote 838 Medicare prescriptions that cost $805K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mometasone Furoate Generic | 93 | 97 | 65 | $1,582 |
| Clobetasol Propionate Generic | 75 | 75 | 51 | $3,758 |
| Mupirocin Generic | 56 | 57 | 45 | $511 |
| Prednisone Generic | 44 | 55 | 11 | $363 |
| Fluticasone Propionate Generic | 40 | 43 | 32 | $900 |
| Acitretin Generic | 23 | 35 | 12 | $6,273 |
| Mycophenolate Mofetil Generic | 23 | 25 | Under 11 | $3,839 |
| Dupixent Pen Dupilumab | 22 | 22 | Under 11 | $89K |
| Siliq Brodalumab | 21 | 21 | Under 11 | $107K |
| Tacrolimus Generic | 21 | 21 | 18 | $2,148 |
| Terbinafine Hcl Generic | 21 | 23 | 11 | $314 |
| Doxycycline Hyclate Generic | 18 | 19 | 15 | $946 |
| Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort | 18 | 19 | Under 11 | $823 |
| Nystatin Generic | 16 | 16 | Under 11 | $272 |
| Gabapentin Generic | 16 | 18 | Under 11 | $290 |
Brand drugs: - claims; generic drugs: 669 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark Lebwohl $154K ($128K in general payments such as food, travel and fees and $26K for research) from 26 companies. The largest payer was Sun Pharmaceutical Industries Inc. with $37K.
| Company | Payments | Amount |
|---|---|---|
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 27 | $37K |
| Pfizer Inc. PFE | 11 | $15K |
| Boehringer Ingelheim International GmbH | 8 | $14K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $14K |
| LEO Pharma Inc. | 12 | $9,711 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 6 | $8,812 |
| Eli Lilly and Company LLY | 7 | $8,183 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $7,389 |
| Galderma Laboratories, L.P. GALD.SW | 17 | $7,183 |
| Janssen Scientific Affairs, LLC JNJ | 4 | $7,146 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.